|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy显示文摘AIM: To reviewing genetic and epigenetic make-up of metastatic colorectal cancers(m CRCs) addicted to epidermal growth factor receptor(EGFR) signalling.METHODS: The present study summarizes the potential value of prognostic and predictive biomarkers in selecting m CRC patients treated with anti-EGFR therapy. A meta-analysis was performed using a systematic search of Pub Med, Medline and Web of Science to identify eligible papers until March 21 st, 2016 using these following terms: ‘‘colorectal cancer'', 'predictive biomarkers' ', 'anti-EGFR therapy', 'KRAS', 'NRAS'', 'PIK3CA', 'TP53', 'PTEN', ‘‘EGFR', 'MET', 'HER2', 'epiregulin', 'amphiregulin', 'prognostic biomarkers', 'BRAF', 'miR NA' and 'antibody-dependent cell-mediated cytotoxicity(ADCC) activity'. Two investigators independently evaluated and extracted data from each identified studies based on selected criteria of inclusion and exclusion. RESULTS: The introduction of agents targeting EGFR such as cetuximab and panitumumab increased overall survival of mC RCs. Nevertheless, it has firstly became evident that response rates to cetuximab regimens in unselected patient populations were typically lower than 30%. Clinical data confirmed the predictive value of RAS mutations for resistance to cetuximab and panitumumab leading to the license of these monoclonal antibodies exclusively for the management of patients with RAS-wild type colorectal cancers. So far the identification of predictive biomarkers have generated interesting, though preliminary and, at times, conflicting data on the importance of tumour mR NA levels of EGFR ligands, of activating mutations in other genes such as NRAS and PIK3 CA. The prognostic value of selected micro RNAs level and ADCC activity is under investigation, while the prognostic impact of BRAF status remains controversial.CONCLUSION: This review focuses on the personalized treatment of m CRC and discusses the potential of new prognostic and predictive biomarkers in selecting patients treated with anti-EGFR therapy. | Cristiana Lo Nigro Vincenzo Ricci Daniela Vivenza Cristina Granetto Teresa Fabozzi Emanuela Miraglio Marco C Merlano | 2016 | World Journal of Gastroenterology2016，22，30： | 5 |
| 2 | Evaluation of antibody-dependent cell-mediatedcy totoxicity activity and cetuximab response in KRAS wildtype metastatic colorectal cancer patients显示文摘AIM:To investigate the prognostic role of invariant natural killer T(iNKT) cells and antibody-dependent cell-mediated cytotoxicity(ADCC) in wild type KRAS metastatic colorectal cancer(mC RC) patients treated with cetuximab.METHODS: Forty-one KRAS wt mC RC patients,treated with cetuximab and irinotecan-based chemotherapy in Ⅱ and Ⅲ lines were analyzed. Genotyping of single nucleotide polymorphism(SNP)s in the FCGR2A,FCGR3A and in the 3' untranslated regions of KRAS and mutational analysis for KRAS,BRAF and NRAS genes was determined either by sequencing or allelic discrimination assays. Enriched NK cells were obtained from lymphoprepperipheral blood mononuclear cell and iN KT cells were defined by co-expression of CD3,TCRVα24,TCRVβ11. ADCC was evaluated as ex vivo NK-dependent activity,measuring lactate dehydrogenase release.RESULTS: At basal,mCRC patients performing ADCC activity above the median level(71%) showed an improved overall survival(OS) compared to patients with ADCC below(median 16 vs 8 mo;P=0.026). We did not find any significant correlation of iN KT cells with OS(P=0.19),albeit we observed a trend to a longer survival after 10 mo in patients with iN KT above median basal level(0.382 cells/microliter). Correlation of OS and progression-free survival(PFS) with interesting SNPs involved in ADCC ability revealed not to be significant. Patients carrying alleles both with A in FCGR2 A and TT in FCGR3A presented a trend of longer PFS(median 9 vs 5 mo;P=0.064). Chemotherapy impacted both iN KT cells and ADCC activity. Their prognostic values get lost when we analysed them after 2 and 4 mo of treatment.CONCLUSION: Our results suggest a link between iN KT cells,basal ADCC activity,genotypes in FCGR2A and FCGR3A,and efficacy of cetuximab in KRAS wt mC RC patients. | cristiana lo nigro vincenzo ricci daniela vivenza martino monteverde giuliana strola francesco lucio federica tonissi emanuela miraglio cristina granetto mirella fortunato marco carlo merlano | 2016 | World Journal of Gastrointestinal Oncology2016，8，2： | 2 |
| 3 | Best supportive care in non small cell lung cancer:Is there a role for radiotherapy and chemotherapy显示文摘 | Numico G Russi E Merlano M | | 0，，03： | 1 |
| 4 | Paclitaxel,cisplatin ,5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase Ⅱ trial 显示文摘 | MERLANO M RUSSI E G NUMICO G | 2005 | Radiother Oncol2005，75，2： | 1 |
| 5 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer显示文摘 | Bertelli G Garrone O Merlano M | 2005 | Oncology2005，69，6： | 1 |
| 6 | Aortic perforation due to cardiac resynchronisation therapy defibrillator lead placement:Case report and medicolegal considerations显示文摘 | Grande AM Fiore A Merlano M | 2015 | J Arrhythm2015，31，： | 1 |
| 7 | Best supportive care in non small cell lung cancer; is it here a role for radiotherapy and chemotherapy显示文摘 | Numico C Russi E Merlano M | 2001 | Lung Cancer2001，32，3： | 1 |
| 8 | Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck显示文摘 | Merlano M Occelli M | 2007 | Ther Clin Risk Manag2007，3，5： | 1 |
| 9 | Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck显示文摘 | Merlano M Occelli M | 2007 | Ther Clin Risk Manag2007，3，5： | 1 |
| 10 | The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer显示文摘 | Nerina Denaro Merlano E g Russi Lo Nigro | 2013 | OncoTargets and Therapy (default)2013，，： | 1 |
| 11 | Routine surveillance of adve=:se events following immunization as an important tool to moni- tor vaccine safety显示文摘 | Alicino C Merlano C Zappettini S | 2015 | Hum Vaccin Immunother2015，11，1： | 1 |
| 12 | Best supportive care in non- small cell lung cancer:is there a role for radiotherapy and chemotherapy显示文摘 | Numico G Russi E Merlano M | 2001 | Lung Cancer2001，32，3： | 1 |
| 13 | Best supportive care in non small cell lung cancer:is it here a role for radiotherapy and chemotherapy显示文摘 | Numico G Russi E Merlano M | 2001 | Lung Cancer2001，32，3： | 1 |
| 14 | Dysphagia in head and neck cancer patients: pretreatment evaluation, pre dictive factors, and assessment during radio-chemotherapy, rec- ommendations显示文摘 | Nerina Denaro Marco C Merlano Elvio G | 2013 | Clin Exp Otorhinolaryngol2013，6，3： | 1 |
| 15 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer 显示文摘 | Bertelli G Garrone O Merlano M | 2005 | Oncology2005，69，6： | 1 |
| 16 | Sequential treatmentwith exemestane and non-steroidal aromatase inhibitors in advanced breast cancer显示文摘 | Bertelli G Garrone O Merlano M | 2005 | Ontology2005，69，6： | 1 |
| 17 | Sequential use of aromatse inactivators and inhitors and inhibitor in advanced breast cancer显示文摘 | Bertelli G Garrone O Merlano M | 2002 | Proc Am Soc Clin 0ncol2002，21，： | 1 |
| 18 | Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy显示文摘 | Merlano M Vitale V Rosso R | 1992 | N Engl J Med1992，327，： | 1 |
| 19 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer显示文摘 | Bertelli G Garrone O Merlano M | | 0，，： | 1 |
| 20 | Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: A phase II clinical study 显示文摘 | Merlano M Russi E Benasso M | 2011 | Ann Oncol2011，22，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员